Deep Expertise Across Functional Areas
Bringing together industry experts, blue-chip investors, and a cross-disciplinary team of top scientists in antibody drug discovery and disease biology, we are translating therapeutics into the clinic. Meet our Leadership Team:
Dr. Vickers is the Chief Executive Officer of Northern Biologics, and a member of the Northern Biologics Board of Directors. Prior to joining Northern Biologics, Dr. Vickers served as Global Head of Research and Development and a member of the Executive Committee of Shire, a biotechnology company focused on the development of therapies for the treatment of rare and specialty conditions. Under Dr. Vickers’s leadership Shire’s pipeline had approximately 40 programs in clinical development in the areas of Genetic Disease, GI disease, Hematology, Immunology, Neuroscience, Ophthalmology and Oncology. Prior to Shire, Dr. Vickers held positions of increasing responsibility in Research and Development at Merck, Pfizer, Boehringer-Ingelheim and Resolvyx Pharmaceuticals. Dr. Vickers is also a member of the Board of Directors of Revance Therapeutics and AVROBIO.
Dr. Vickers obtained his PhD in Biochemistry from the University of Toronto, which was followed by postdoctoral research in mechanisms of multidrug resistance in breast cancer at the National Cancer Institute in Bethesda, Maryland.
Darlene Deptula-Hicks joined Northern Biologics in March 2018 as consulting Chief Financial Officer. Ms. Deptula-Hicks, is an accomplished financial executive in the life sciences and medical technology industries and has nearly 30 years’ experience leading financial operations for both public and private companies. She brings to Northern Biologics a proven track record in finance strategy leadership, capital raising, mergers and acquisitions, operational management and the ability to build strong, external partnerships. Prior to Northern Biologics, Ms. Dupta-Hicks served as Sr. Vice President and Chief Financial Officer and Treasurer of T2 Biosystems, Inc. (NASDAQ:TTOO) and Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) where she was responsible for financial strategy, capital formation, compliance and reporting and investor relations. Prior to T2 and Pieris, Ms.Deptula-Hicks served as the CFO for a variety of biotechnology and medical device companies, including in the areas of oncology, genomics, minimally invasive surgery, advanced image analysis, radiation oncology, cardiology and orthopedics, among other specialties.
Ms. Deptula-Hicks completed an executive education program at Dartmouth College’s Tuck School of Business and received her MBA from Rivier College. She received her bachelor’s in accounting from Southern New Hampshire University, and has served on a variety of public and private company boards.
Dr. Anido joined Northern Biologics as VP of Operations and Corporate Affairs in June 2017. Previously, Dr. Anido was co-founder of Mosaic Biomedicals, a Barcelona-based company that develops personalized cancer treatments with a dual mechanism of action targeting cancer stem cells and the tumor’s immune system. As Mosaic’s CEO, Dr. Anido led the growth of the company until its merger with Northern in 2016. Prior to Mosaic, Dr. Anido was Associate at the Pipeline and Portfolio Planning team collaborating with the Oncology & Hemathology Franchise at Genentech Inc. (CA, US).
Dr. Anido holds a Master in Business Administration (MBA) from Duke University (NC, US) with a certification in Health Sector Management and concentration in Entrepreneurship and Innovation. In addition, she received her PhD from the University of Barcelona (Spain) and has over 10 years of scientific career in translational oncology at the Vall d’Hebron Institute of Oncology (Spain). Dr. Anido is a recipient of merit-based scholarships from the Spanish Association Against Cancer (AECC), Rafael del Pino Foundation, Caja Madrid Foundation and Duke University’s Julian Connally Scholarship.
Dr. Hulme is Vice-President and Head of Research at Northern Biologics. Dr. Hulme joined Northern Biologics in 2015 as Director of Fibrosis, where she led the fibrosis team and developed and advanced several innovative antibody therapeutics for the treatment of fibrotic diseases. In 2018 Dr. Hulme assumed the leadership of Northern's immuno-oncology portfolio and in 2019 was promoted to Vice-President and Head of Research. Prior to joining Northern Biologics, Dr. Hulme held positions of increasing responsibility in Inflammation Research at Amgen. During her eight years at Amgen, Dr. Hulme led cross-functional preclinical teams developing innovative small molecule and protein therapeutics for inflammatory diseases, fibrosis and immuno-oncology.
Dr. Hulme obtained her PhD in Pharmacology from the University of Leeds, UK, which was followed by postdoctoral research in mechanisms of ion channel regulation at the University of Washington, Seattle.